MILAN, ITALY--(Marketwire - Aug. 5, 2011) - MolMed S.p.A. (MILAN:MLM) today announced that it has signed an agreement with GlaxoSmithKline (GSK) under which MolMed will develop a production process for an investigational gene therapy for ADA-SCID (Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency), a very rare and life-threatening disease that affects approximately 350 children worldwide. Under the terms of the agreement, MolMed will receive up to ? 5.5 million in revenues over a two-year period.